Last updated: October 23, 2026
Eliglustat tartrate, marketed by Sanofi as Cerdelga, is an oral substrate-reduction therapy for adults with Gaucher disease type 1. Its commercial position rests on chronic treatment, oral administration, pharmacogenomic dosing, and limited competition in a rare-disease market. Sanofi’s main risks are enzyme-replacement-therapy competition, payer controls, CYP2D6 testing requirements, future generic entry, and the gradual maturation of Gaucher disease treatment.
The product’s U.S. orphan-drug exclusivity expired in August 2021. Its commercial protection now depends mainly on patents, regulatory barriers, manufacturing know-how, physician familiarity, and the small size of the eligible patient population.
What is eliglustat tartrate and how is it used?
Eliglustat tartrate is the tartrate salt of eliglustat, a glucosylceramide synthase inhibitor. It reduces the production of glucosylceramide, the substrate that accumulates in Gaucher disease.
Cerdelga is approved for adults with Gaucher disease type 1 who are extensive, intermediate, or poor metabolizers of CYP2D6. Ultra-rapid metabolizers are generally not appropriate candidates because exposure may be insufficient. The FDA label requires CYP2D6 genotype information before treatment selection and identifies important interactions with CYP2D6 and CYP3A inhibitors and inducers.[1]
| Product attribute |
Eliglustat tartrate |
| Brand |
Cerdelga |
| Active ingredient |
Eliglustat |
| Developer and marketer |
Sanofi |
| Initial U.S. approval |
August 19, 2014 |
| FDA indication |
Adults with Gaucher disease type 1 |
| Administration |
Oral capsules |
| Primary mechanism |
Glucosylceramide synthase inhibition |
| Key diagnostic requirement |
CYP2D6 metabolizer status |
| Main alternative |
Enzyme-replacement therapy |
| Principal commercial market |
Rare-disease, chronic specialty pharmacy |
The oral route is commercially important because the principal alternatives, including imiglucerase, velaglucerase alfa, and taliglucerase alfa, are administered by intravenous infusion.
How large is the eliglustat tartrate market?
The eliglustat market is a small, high-value specialty pharmaceutical segment rather than a mass-market product category. Market size is driven by treated Gaucher disease type 1 patients, persistence on chronic therapy, geographic reimbursement, and conversion from infusion-based enzyme replacement.
Public sources do not provide a consistently reported, independently auditable global market figure for eliglustat alone. Sanofi reports Cerdelga within its rare-disease portfolio and has not always presented a complete standalone revenue series in the same format across annual reporting periods.[2]
The commercial model has several favorable characteristics:
- Gaucher disease is chronic and usually requires long-term treatment.
- Patients who respond to oral therapy may remain on treatment for years.
- The eligible population is concentrated among specialist physicians and centers.
- Switching costs include clinical monitoring, pharmacogenomic assessment, and patient preference.
- Generic substitution is more difficult than in a conventional primary-care market because of the small patient pool and specialist prescribing base.
The limiting factor is the size of the diagnosed and treated population. Eliglustat cannot expand indefinitely through conventional primary-care prescribing. Growth depends on diagnosis, treatment penetration, geographic reimbursement, and conversion from enzyme replacement.
What is driving the financial trajectory of Cerdelga?
Cerdelga’s revenue trajectory is principally a function of patient additions, treatment persistence, price realization, and geographic access. It is less dependent on large volume growth than on maintaining a high annual value per treated patient.
Positive revenue drivers
- Expansion of oral-treatment use among eligible Gaucher disease type 1 patients.
- Conversion from intravenous enzyme replacement.
- Improved diagnosis of Gaucher disease.
- Continued reimbursement in the United States and major European markets.
- Long treatment duration and relatively low discontinuation once patients stabilize.
- Sanofi’s established rare-disease infrastructure.
Negative revenue drivers
- A finite global patient population.
- Competition from established enzyme-replacement products.
- Eligibility limitations based on CYP2D6 metabolism.
- Drug-drug interaction concerns.
- Payer restrictions and prior authorization.
- Price pressure as patent protection weakens.
- Potential generic entry after enforceable patent barriers expire.
- Patient retention challenges when switching from a familiar enzyme-replacement regimen.
Cerdelga’s financial profile is therefore best characterized as a mature rare-disease franchise with durable cash generation but limited structural volume growth. The product is unlikely to produce the scale of Sanofi’s major vaccines or immunology brands, but it can remain economically relevant because rare-disease pricing and chronic use support substantial revenue per patient.
How does eliglustat compare with enzyme-replacement therapy?
Eliglustat competes most directly with enzyme-replacement therapies rather than with ordinary oral generics.
| Factor |
Eliglustat |
Enzyme-replacement therapy |
| Route |
Oral |
Intravenous infusion |
| Treatment setting |
Home or outpatient oral treatment |
Infusion center or home infusion |
| Patient selection |
Requires CYP2D6 assessment |
Does not require CYP2D6 selection |
| Main convenience advantage |
Avoids routine infusions |
Established long-term clinical use |
| Primary limitation |
Drug interactions and genotype restrictions |
Infusion burden and administration cost |
| Switching barrier |
Clinical confidence and patient stability |
Longstanding physician familiarity |
| Generic substitution risk |
Potentially significant after patent expiry |
Limited because products are biologics |
Sanofi’s Cerezyme, Shire/Takeda’s Vpriv, and Pfizer’s Elelyso remain relevant comparators. Miglustat is also an oral substrate-reduction therapy, but it has a different tolerability and clinical positioning profile and is not a direct one-for-one substitute in every patient.
What is the FDA regulatory status of eliglustat?
The FDA approved Cerdelga under NDA 205494 on August 19, 2014. The approval covered adults with Gaucher disease type 1 who fall within specified CYP2D6 metabolizer categories.[1]
The regulatory position has several commercial implications:
- The original five-year new-chemical-entity exclusivity period ended in 2019.
- Seven-year orphan-drug exclusivity ended in August 2021.
- Pediatric exclusivity, if granted for a particular product, would extend certain regulatory protections but would not independently create a new patent term.
- Any follow-on applicant must address FDA-listed patents and applicable regulatory exclusivities.
- A generic applicant would generally use an abbreviated new drug application, while a biologic competitor would use a biosimilar pathway. Eliglustat is a small molecule, so biosimilar rules do not apply.
What patents protect eliglustat tartrate?
The principal U.S. patent estate has included composition, pharmaceutical-composition, formulation, and treatment-related claims. Patent coverage has been associated with Sanofi and predecessor Genzyme entities.
A commonly cited U.S. patent associated with eliglustat is U.S. Patent No. 8,410,131. Its effective expiration depends on the patent’s term adjustment, terminal disclaimers, and any applicable regulatory patent-term extension. Secondary patent databases often display different dates because they may use estimated expiration dates rather than the enforceable term recorded by the U.S. Patent and Trademark Office.
| Protection category |
Commercial relevance |
| Active pharmaceutical ingredient |
Can delay direct generic substitution |
| Tartrate salt and solid-state forms |
May protect the marketed chemical form |
| Capsule composition |
Can restrict formulation copying |
| Dosing and treatment methods |
May create litigation exposure for proposed labels |
| Manufacturing processes |
Can raise process-development and scale-up costs |
| International patents |
May create country-specific launch timing |
A complete freedom-to-operate analysis must review the current FDA Orange Book, USPTO records, patent-family continuity, terminal disclaimers, patent-term adjustment, and litigation history. The Orange Book is the controlling source for patents listed against an approved small-molecule product.[3]
What formulations are protected?
The commercial product is an oral capsule containing eliglustat. Formulation protection may cover the salt form, excipient combination, dosage strength, release characteristics, capsule composition, or manufacturing process.
Formulation patents are commercially important even when the basic active-ingredient patent has expired. A generic applicant may attempt to design around a formulation claim by using a different excipient system or dosage form. That strategy can still create regulatory and litigation risk if the proposed product would be used under a patent-protected method or if an Orange Book-listed patent remains enforceable.
When does eliglustat lose exclusivity?
Eliglustat has already lost its principal statutory regulatory exclusivities. The relevant dates are:
| Event |
Date or status |
| U.S. approval |
August 19, 2014 |
| Five-year new-chemical-entity exclusivity |
Ended in 2019 |
| Seven-year orphan-drug exclusivity |
Ended August 19, 2021 |
| Patent-based protection |
Depends on each patent family and term adjustment |
| Generic entry |
Dependent on ANDA filings, Paragraph IV litigation, settlements, and enforceable patent claims |
The end of orphan exclusivity did not automatically authorize generic entry. Patent claims can continue to block approval or commercial launch after regulatory exclusivity has ended.
What Paragraph IV challenges and litigation risks exist?
A Paragraph IV certification would assert that an Orange Book-listed patent is invalid, unenforceable, or not infringed. If a first applicant submits a valid Paragraph IV certification and the brand owner files suit within the statutory period, FDA approval may be subject to a 30-month stay, subject to statutory exceptions.[4]
For eliglustat, the most important litigation questions are:
- Whether any active Orange Book-listed patents remain.
- Whether the listed claims cover the active ingredient, salt, formulation, or method of use.
- Whether a generic applicant can omit patented indications through a section viii statement.
- Whether Sanofi could establish infringement based on the proposed label.
- Whether patent settlements would include launch dates, licenses, or restrictions.
- Whether a generic manufacturer can source non-infringing active pharmaceutical ingredient.
No broad biosimilar challenge applies because eliglustat tartrate is a small-molecule drug. The likely competitive event is an ANDA-based generic challenge, not a biosimilar filing.
Which companies challenge or compete with eliglustat?
The competitive field includes both branded enzyme-replacement companies and potential generic manufacturers.
| Company |
Relevant product or position |
| Sanofi |
Cerdelga and Cerezyme |
| Takeda |
Vpriv and Gaucher disease specialty infrastructure |
| Pfizer |
Elelyso |
| Generic manufacturers |
Potential future ANDA applicants |
| Specialty distributors |
Access, inventory, and reimbursement channel participants |
The strongest current competition comes from alternative treatment modalities, not direct generic substitution. Physicians may select enzyme replacement when CYP2D6 status, drug interactions, pregnancy considerations, tolerability, or clinical experience make eliglustat less attractive.
What generic entry scenarios exist?
Three scenarios are commercially plausible.
Early patent challenge
A generic applicant files a Paragraph IV certification before the final patent barrier expires. Sanofi litigates, potentially securing a 30-month stay or settlement. The outcome depends on claim validity, infringement, and settlement terms.
Authorized or licensed generic entry
Sanofi may license another manufacturer or commercialize an authorized generic. This could preserve part of the franchise value while reducing external litigation exposure.
Post-patent market entry
Multiple generic manufacturers enter after the enforceable patent estate expires. Prices decline, payer substitution increases, and Sanofi’s branded share falls. The small patient population may limit the number of economically viable entrants.
Generic entry may be slower than in high-volume drugs because market opportunity is limited, production requires specialized quality controls, and prescriber concentration increases commercial barriers.
What licensing deals affect eliglustat tartrate?
Sanofi acquired Genzyme in 2011, bringing Cerdelga-related development and commercialization rights into the Sanofi portfolio. The main strategic transaction relevant to eliglustat is therefore the Genzyme acquisition rather than a later standalone out-license.[5]
Sanofi’s ownership of the rare-disease infrastructure creates efficiencies across Cerdelga, Cerezyme, Fabrazyme, and other specialty products. That infrastructure supports patient identification, specialist relationships, reimbursement operations, and pharmacovigilance.
How strong is the eliglustat patent estate?
The estate is commercially meaningful but no longer supported by regulatory exclusivity. Its strength depends on the surviving claims rather than on the number of patents alone.
Strengths
- Rare-disease specialist prescribing limits immediate commercial substitution.
- Oral treatment provides a differentiated value proposition.
- Formulation and method-of-use claims may complicate generic design-around.
- Manufacturing controls can raise entry costs.
- Long-term patient persistence supports brand retention.
Weaknesses
- Orphan-drug exclusivity has expired.
- The product is a small molecule and is technically eligible for generic competition.
- CYP2D6 restrictions narrow the addressable market.
- Enzyme-replacement products remain clinically established.
- Patent claims may be vulnerable to validity challenges as expiration approaches.
- A small market can support only limited brand defense after generic entry.
What is the geographic coverage of eliglustat?
Cerdelga has been marketed in the United States and multiple international markets, including Europe, subject to country-specific approvals and reimbursement decisions. Commercial performance varies by:
- National Gaucher disease diagnosis rates.
- Reimbursement for oral specialty medicines.
- Use of enzyme replacement as the default standard.
- Availability of CYP2D6 testing.
- Local patent terms and supplementary protection certificates.
- Hospital and specialty-pharmacy distribution rules.
U.S. revenue is likely to remain strategically important because of specialty-drug pricing and centralized rare-disease support. European markets provide breadth but generally impose tighter health-technology assessment and price controls.
What manufacturing and intellectual-property barriers remain?
Manufacturing barriers include control of the active pharmaceutical ingredient, salt formation, polymorph control, capsule uniformity, dissolution testing, analytical methods, and process validation. These factors can delay a generic launch even when the legal patent position is weakening.
The most defensible commercial assets are likely to be the integrated package of formulation know-how, regulatory experience, specialist access, pharmacogenomic education, and patient-support infrastructure. These assets do not prevent legal entry but can preserve branded volume after entry.
Key Takeaways
- Eliglustat tartrate is Sanofi’s oral Cerdelga treatment for adults with Gaucher disease type 1.
- Its commercial value comes from chronic use, oral administration, and rare-disease pricing.
- FDA new-chemical-entity exclusivity ended in 2019, and orphan-drug exclusivity ended in August 2021.
- Future exclusivity depends on the remaining patent estate, including composition, formulation, method-of-use, and manufacturing claims.
- The main current competitors are enzyme-replacement therapies, not biosimilars.
- Generic entry would most likely occur through an ANDA and could involve Paragraph IV litigation.
- Revenue growth is constrained by the small patient population but supported by long treatment duration and specialist-market economics.
- Sanofi’s Genzyme acquisition provides the principal licensing and commercialization foundation for the product.
- The strongest post-patent defenses are patient persistence, specialist distribution, pharmacogenomic workflow, and manufacturing complexity.
FAQs About Eliglustat Tartrate
Is eliglustat tartrate the same as Cerdelga?
Yes. Cerdelga is the Sanofi brand containing eliglustat tartrate.
Is eliglustat a biologic drug?
No. Eliglustat is a small-molecule drug. A future competitor would generally use the generic-drug pathway rather than the biosimilar pathway.
Does eliglustat require genetic testing?
Yes. CYP2D6 metabolizer status is central to determining whether an adult patient is an appropriate candidate and what dose should be used.[1]
Can a generic manufacturer copy the Cerdelga capsule?
A generic manufacturer must satisfy FDA requirements for pharmaceutical equivalence and bioequivalence and must address applicable patents. It may need to design around formulation, method-of-use, or manufacturing claims.
What is the principal commercial threat to Cerdelga?
The largest near-term commercial threat is the combination of mature Gaucher disease treatment penetration, enzyme-replacement competition, payer controls, and eventual generic entry after enforceable patent protection expires.
References
-
U.S. Food and Drug Administration. (2023). Cerdelga (eliglustat) prescribing information. FDA.
-
Sanofi. (2023). Universal registration document and annual financial report 2023. Sanofi.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Refuse-to-receive standards and Paragraph IV certifications. FDA.
-
Sanofi. (2011). Sanofi completes acquisition of Genzyme. Sanofi press release.
